Correlation Between Agios Pharm and Nautilus Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Agios Pharm and Nautilus Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Agios Pharm and Nautilus Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Agios Pharm and Nautilus Biotechnology, you can compare the effects of market volatilities on Agios Pharm and Nautilus Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Agios Pharm with a short position of Nautilus Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Agios Pharm and Nautilus Biotechnology.

Diversification Opportunities for Agios Pharm and Nautilus Biotechnology

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Agios and Nautilus is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Agios Pharm and Nautilus Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nautilus Biotechnology and Agios Pharm is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Agios Pharm are associated (or correlated) with Nautilus Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nautilus Biotechnology has no effect on the direction of Agios Pharm i.e., Agios Pharm and Nautilus Biotechnology go up and down completely randomly.

Pair Corralation between Agios Pharm and Nautilus Biotechnology

Given the investment horizon of 90 days Agios Pharm is expected to generate 0.57 times more return on investment than Nautilus Biotechnology. However, Agios Pharm is 1.77 times less risky than Nautilus Biotechnology. It trades about -0.03 of its potential returns per unit of risk. Nautilus Biotechnology is currently generating about -0.18 per unit of risk. If you would invest  3,303  in Agios Pharm on December 29, 2024 and sell it today you would lose (219.00) from holding Agios Pharm or give up 6.63% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Agios Pharm  vs.  Nautilus Biotechnology

 Performance 
       Timeline  
Agios Pharm 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Agios Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Agios Pharm is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.
Nautilus Biotechnology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Nautilus Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Agios Pharm and Nautilus Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Agios Pharm and Nautilus Biotechnology

The main advantage of trading using opposite Agios Pharm and Nautilus Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Agios Pharm position performs unexpectedly, Nautilus Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nautilus Biotechnology will offset losses from the drop in Nautilus Biotechnology's long position.
The idea behind Agios Pharm and Nautilus Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance